2020-07-16
Camurus' Interim Report Second Quarter 2020
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read the full report on Camurus' website: https://www.camurus.com/financial-reports/
2020-07-16
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read the full report on Camurus' website: https://www.camurus.com/financial-reports/
2020-07-16
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read more2020-06-24
Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…
Read more2020-06-23
The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…
Read more2020-05-07
”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read more2020-04-08
Camurus Annual Report for 2019 is now available at the company´s website.
Read more